January 27, 2015 at 07:26PM CSL Biotherapies Untitled Letter

Deviations from current good manufacturing practice (CGMP) requirements in the manufacture of licensed biological vaccine products and monovalent influenza bulks.



via What's New: Vaccines, Blood & Biologics RSS Feed http://ift.tt/15PG7mS